Vanguard Group
RNAC icon

Vanguard Group’s Cartesian Therapeutics RNAC Stock Holding History

Vanguard Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.9M Buy
541,228
+20,506
+4% +$166K ﹤0.01% 3349
2025
Q3 		$5.32M Buy
520,722
+24,356
+5% +$274K ﹤0.01% 3257
2025
Q2 		$5.16M Sell
496,366
-7,171
-1% -$76.4K ﹤0.01% 3207
2025
Q1 		$6.64M Buy
503,537
+74,057
+17% +$1.32M ﹤0.01% 3065
2024
Q4 		$7.69M Buy
429,480
+186,391
+77% +$3.77M ﹤0.01% 3082
2024
Q3 		$3.92M Buy
243,089
+6,432
+3% +$100K ﹤0.01% 3359
2024
Q2 		$6.39M Buy
236,657
+26,153
+12% +$624K ﹤0.01% 3141
2024
Q1 		$4.1M Sell
210,504
-30,964
-13% -$656K ﹤0.01% 3375
2023
Q4 		$4.99M Buy
241,468
+1,757
+0.7% +$52.4K ﹤0.01% 3293
2023
Q3 		$7.62M Buy
239,711
+2,856
+1% +$95.4K ﹤0.01% 3050
2023
Q2 		$7.96M Buy
236,855
+16,342
+7% +$585K ﹤0.01% 3073
2023
Q1 		$9.2M Buy
220,513
+8,423
+4% +$396K ﹤0.01% 2982
2022
Q4 		$7.19M Buy
212,090
+7,208
+4% +$307K ﹤0.01% 3117
2022
Q3 		$10.1M Buy
204,882
+20,479
+11% +$1.12M ﹤0.01% 2951
2022
Q2 		$7.25M Sell
184,403
-5,271
-3% -$156K ﹤0.01% 3169
2022
Q1 		$7M Buy
189,674
+17,400
+10% +$1.09M ﹤0.01% 3347
2021
Q4 		$16.8M Buy
172,274
+3,474
+2% +$374K ﹤0.01% 2932
2021
Q3 		$21.1M Buy
168,800
+973
+0.6% +$117K ﹤0.01% 2838
2021
Q2 		$21M Buy
167,827
+3,022
+2% +$360K ﹤0.01% 2813
2021
Q1 		$22.4M Sell
164,805
-1,857
-1% -$231K ﹤0.01% 2727
2020
Q4 		$15.2M Buy
166,662
+10,884
+7% +$944K ﹤0.01% 2775
2020
Q3 		$11.6M Buy
155,778
+32,531
+26% +$2.49M ﹤0.01% 2715
2020
Q2 		$10.5M Buy
123,247
+69,352
+129% +$6.29M ﹤0.01% 2744
2020
Q1 		$3.9M Buy
53,895
+8,999
+20% +$869K ﹤0.01% 3073
2019
Q4 		$3.21M Sell
44,896
-5,290
-11% -$255K ﹤0.01% 3316
2019
Q3 		$2.63M Sell
50,186
-3,824
-7% -$203K ﹤0.01% 3359
2019
Q2 		$2.9M Buy
54,010
+3,660
+7% +$249K ﹤0.01% 3361
2019
Q1 		$3.58M Buy
50,350
+41,150
+447% +$2.61M ﹤0.01% 3262
2018
Q4 		$734K Sell
9,200
-12,659
-58% -$2.89M ﹤0.01% 3648
2018
Q3 		$10.2M Buy
21,859
+229
+1% +$92K ﹤0.01% 2909
2018
Q2 		$8.6M Buy
21,630
+1,762
+9% +$625K ﹤0.01% 2974
2018
Q1 		$6.07M Buy
19,868
+587
+3% +$167K ﹤0.01% 3063
2017
Q4 		$5.67M Buy
19,281
+2,052
+12% +$897K ﹤0.01% 3082
2017
Q3 		$9.43M Buy
17,229
+9,975
+138% +$5.31M ﹤0.01% 2839
2017
Q2 		$4.32M Buy
7,254
+4,621
+176% +$2.04M ﹤0.01% 3137
2017
Q1 		$1.13M Buy
2,633
+372
+16% +$157K ﹤0.01% 3546
2016
Q4 		$1.16M Sell
2,261
-1,660
-42% -$970K ﹤0.01% 3515
2016
Q3 		$1.68M Sell
3,921
-79
-2% -$30.9K ﹤0.01% 3443
2016
Q2 		$1.68M Buy
+4,000
New +$1.68M ﹤0.01% 3433

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group's RNAC Position: Q4 2025 in Review

Vanguard Group increased its Cartesian Therapeutics (RNAC) stake by 3.9% in Q4 2025, buying an estimated $166K and bringing the position to 541,228 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3349.

Vanguard Group first reported a position in RNAC in Q2 2016 and has held it in 39 quarters since. The position peaked at $22.4M in Q1 2021. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

  • Vanguard Group held 541,228 shares of Cartesian Therapeutics worth $3.9M as of Q4 2025.
  • Vanguard Group bought 20,506 Cartesian Therapeutics shares in Q4 2025, an estimated $166K.
  • Cartesian Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3349 holding.
  • Vanguard Group first reported a position in Cartesian Therapeutics in Q2 2016 and has held it in 39 quarters since.
  • Vanguard Group's Cartesian Therapeutics position peaked at $22.4M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.